Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Kiora Pharmaceuticals (KPRX) EBITDA Margin (2016 - 2024)

Kiora Pharmaceuticals' EBITDA Margin history spans 9 years, with the latest figure at 83.57% for Q1 2024.

  • For Q1 2024, EBITDA Margin changed N/A year-over-year to 83.57%; the TTM value through Dec 2024 reached 21.85%, changed N/A, while the annual FY2024 figure was 21.85%, N/A changed from the prior year.
  • EBITDA Margin reached 83.57% in Q1 2024 per KPRX's latest filing, down from 550467.02% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 550467.02% in Q3 2022 to a low of 10854.28% in Q4 2020.
  • Average EBITDA Margin over 4 years is 186945.6%, with a median of 144473.91% recorded in 2021.
  • The largest YoY upside for EBITDA Margin was 16111525bps in 2021 against a maximum downside of 16111525bps in 2021.
  • A 4-year view of EBITDA Margin shows it stood at 10854.28% in 2020, then skyrocketed by 1484bps to 150260.96% in 2021, then soared by 266bps to 550467.02% in 2022, then tumbled by -100bps to 83.57% in 2024.
  • Per Business Quant, the three most recent readings for KPRX's EBITDA Margin are 83.57% (Q1 2024), 550467.02% (Q3 2022), and 150260.96% (Q4 2021).